Mehrdimensionale psychopharmakologische Untersuchung am Beispiel einer Doppelblindstudie mit Maprotilin

Abstract

Antidepressive therapy with maprotiline was accompanied by blood level determinations psychological clinical and electroencephalographical assessments. It was the aim of the study to introduce objective methods in psychotropic drug therapy and to look for a relationship between blood level and clinical outcome, EEG and psychological data. We found a "therapeutical window" of blood levels between 300 to 600 ng/ml of maprotiline (oral dose of 75 or 150 mg per day). There is also a relationship between clinical outcome rated by the Hamilton-Depression-Scale and the d2-cancellation-test.

Depression in Patients With Epilepsy

“…Serum nomifensine levels here (see Appendix 16), are similar to those reported by Bergener et al (1977) in a study of depressed patients taking the drug for 30 days, and Nawisby (1982) in a pilot study of depressed epileptic patients on 25mg tid for one to 12 weeks. This suggests a difference between nomifensine and amitriptyline, namely that nomifensine is less influenced metabolically by the anticonvulsant drugs; this is one possible reason for the better outcome for the depressed epileptic patients on nomifensine following the increased doses.…”

Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs in Old Age

“…This patient group was compared to a group of 18 female patients (age 34-62 years) treated for 4 weeks with a mean dose of 113 mg Maprotiline/day [1]. Serum samples drawn in the morning were analyzed for Maprotiline by high speed liquid chromatography after derivatization with UV detec tion or directly with oxidative electrochemical detec tion.…”

“…Several factors have to be discussed in the pharmacotherapy of aged patients: (1) The absorption rate of the drug can be lowered due to the aging of intestinal tissue. (2) The sensi tivity of the drug receptors (i.e.…”